title: Morphometric prognostic index in breast cancer.
abstract: OBJECTIVE
  To assess the ability of the morphometric prognostic index (MPI) in predicting clinical outcome in a group of breast cancer patients with short-term follow-up and to assess the relationship between MPI and other prognosticators.
  
  
  METHODS
  The study group consisted of 63 cases of breast cancer. Follow-up data were available for 48 patients. MPI values were calculated, and degree of nuclear and tubular differentiation was investigated in each tumor. S-phase fraction (SPF), estrogen and progesterone receptors were also studied.
  
  
  RESULTS
  The group of patients with MPI values < 0.60 had percent values of disease-free survival significantly higher than did those with MPI values > or = 0.60. Furthermore, significant direct correlations were found between MPI and degree of nuclear atypia and between MPI and SPF. Significant inverse relationships were found between MPI and tumor progesterone receptor levels and between MPI and degree of histologic tubular differentiation.
  
  
  CONCLUSIONS
  The validity of MPI as a prognosticator in breast cancer was confirmed, even in a limited number of patients observed in short-term follow-up. MPI seems to be a reliable and economical prognosticator in selecting breast cancer patients for adjuvant chemotherapy.
authors.affiliation: Institutes of Pathological Anatomy, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Carbone
authors.forename: F G
authors.initials: FG
authors.lastname: Serra
authors.forename: A
authors.initials: A
authors.lastname: Rinelli
authors.forename: D
authors.initials: D
authors.lastname: Terribile
authors.forename: M
authors.initials: M
authors.lastname: Valentini
authors.forename: R
authors.initials: R
authors.lastname: Bellantone
authors.forename: S
authors.initials: S
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Ausili-Cèfaro
authors.forename: L
authors.initials: L
authors.lastname: Nardone
authors.forename: M
authors.initials: M
authors.lastname: Piantelli
authors.forename: A
authors.initials: A
authors.lastname: Capelli
authors.forename: F O
authors.initials: FO
authors.lastname: Ranelletti
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D003600:Cytosol / Q000737:chemistry; D004273:DNA, Neoplasm / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019044:Image Cytometry / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008875:Middle Aged; D008940:Mitotic Index; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016196:S Phase
chemical_list: D004273:DNA, Neoplasm; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone